Immunologic Research

, 44:84

Mutations of the Wiskott–Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes

Article

Abstract

Mutations of the Wiskott–Aldrich Syndrome Protein (WASP) are responsible for classic Wiskott–Aldrich Syndrome (WAS), X-linked thrombocytopenia (XLT), and in rare instances congenital X-linked neutropenia (XLN). WASP is a regulator of actin polymerization in hematopoietic cells with well-defined functional domains that are involved in cell signaling and cell locomotion, immune synapse formation, and apoptosis. Mutations of WASP are located throughout the gene and either inhibit or disregulate normal WASP function. Analysis of a large patient population demonstrates a strong phenotype–genotype correlation. Classic WAS occurs when WASP is absent, XLT when mutated WASP is expressed and XLN when missense mutations occur in the Cdc42-binding site. However, because there are exceptions to this rule it is difficult to predict the long-term prognosis of a given affected boy solely based on the analysis of WASP expression.

Keywords

Wiskott–Aldrich Syndrome X-linked thrombocytopenia X-linked neutropenia WASP gene Mutation analysis Genotype–phenotype correlation 

References

  1. 1.
    Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich Syndrome. Cell. 1994;78:635–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Wiskott A. Familiärer, angeborener Morbus Werihofii? Monastsschr Kinderheilkd. 1937;68:212–6.Google Scholar
  3. 3.
    Aldrich R, Steinberg A, Campbell D. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatits and bloody diarrhea. Pediatrics. 1954;13:133–9.PubMedGoogle Scholar
  4. 4.
    Blaese RM, Strober W, Brown RS, et al. The Wiskott–Aldrich Syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet. 1968;1:1056–61.PubMedGoogle Scholar
  5. 5.
    Cooper MD, Chae HP, Lowman JT, et al. Wiskott–Aldrich Syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med. 1968;44:499–513.PubMedCrossRefGoogle Scholar
  6. 6.
    Ochs HD, Slichter SJ, Harker LA, et al. The Wiskott–Aldrich Syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980;55:243–52.PubMedGoogle Scholar
  7. 7.
    Sullivan KE, Mullen CA, Blaese RM, et al. A multiinstitutional survey of the Wiskott–Aldrich Syndrome. J Pediatr. 1994;125:876–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Molina IJ, Sancho J, Terhorst C, et al. T cells of patients with the Wiskott–Aldrich Syndrome have a restricted defect in proliferative responses. J Immunol. 1993;151:4383–90.PubMedGoogle Scholar
  9. 9.
    Gallego MD, Santamaria M, Pena J, et al. Defective actin reorganization and polymerization of Wiskott–Aldrich T cells in response to CD3-mediated stimulation. Blood. 1997;90:3089–97.PubMedGoogle Scholar
  10. 10.
    Park JY, Shcherbina A, Rosen FS, et al. Phenotypic perturbation of B cells in the Wiskott–Aldrich Syndrome. Clin Exp Immunol. 2005;139:297–305.PubMedCrossRefGoogle Scholar
  11. 11.
    Westerberg L, Larsson M, Hardy SJ, et al. Wiskott–Aldrich Syndrome Protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood. 2005;105:1144–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP Confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B cell homeostasis and function. Blood. 2008;112:4139–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Meyer-Bahlburg A, Becker-Herman S, Humblet-Baron S, et al. Wiskott–Aldrich Syndrome Protein deficiency in B cells results in impaired peripheral homeostasis. Blood. 2008;112:4158–69.PubMedCrossRefGoogle Scholar
  14. 14.
    Orange JS, Ramesh N, Remold-O’Donnell E, et al. Wiskott–Aldrich Syndrome Protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci USA. 2002;99:11351–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Gismondi A, Cifaldi L, Mazza C, et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood. 2004;104:436–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Huang W, Ochs HD, Dupont B, et al. The Wiskott–Aldrich Syndrome Protein regulates nuclear translocation of NFAT2 and NF-kappa B (RelA) independently of its role in filamentous actin polymerization and actin cytoskeletal rearrangement. J Immunol. 2005;174:2602–11.PubMedGoogle Scholar
  17. 17.
    Badolato R, Sozzani S, Malacarne F, et al. Monocytes from Wiskott–Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein–1 and formyl-methionyl-leucyl-phenylalanine. J Immunol. 1998;161:1026–33.PubMedGoogle Scholar
  18. 18.
    Binks M, Jones GE, Brickell PM, et al. Intrinsic dendritic cell abnormalities in Wiskott–Aldrich Syndrome. Eur J Immunol. 1998;28:3259–67.PubMedCrossRefGoogle Scholar
  19. 19.
    de Noronha S, Hardy S, Sinclair J, et al. Impaired dendritic-cell homing in vivo in the absence of Wiskott–Aldrich Syndrome Protein. Blood. 2005;105:1590–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Humblet-Baron S, Sather B, Anover S, et al. Wiskott–Aldrich Syndrome Protein is required for regulatory T cell homeostasis. J Clin Invest. 2007;117:407–18.PubMedCrossRefGoogle Scholar
  21. 21.
    Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott–Aldrich Syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:622–7.CrossRefGoogle Scholar
  22. 22.
    Welch MD, Mullins RD. Cellular control of actin nucleation. Annu Rev Cell Dev Biol. 2002;18:247–88.PubMedCrossRefGoogle Scholar
  23. 23.
    Badour K, Zhang J, Shi F, et al. The Wiskott–Aldrich Syndrome Protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity. 2003;18:141–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell. 2002;10:1269–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Volkman BF, Prehoda KE, Scott JA, et al. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott–Aldrich Syndrome. Cell. 2002;111:565–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Rudolph MG, Bayer P, Abo A, et al. The Cdc42/Rac interactive binding region motif of the Wiskott Aldrich Syndrome Protein (WASP) is necessary but not sufficient for tight binding to Cdc42 and structure formation. J Biol Chem. 1998;273:18067–76.PubMedCrossRefGoogle Scholar
  28. 28.
    Kim AS, Kakalis LT, Abdul-Manan N, et al. Autoinhibition and activation mechanisms of the Wiskott–Aldrich Syndrome Protein. Nature. 2000;404:151–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood. 2002;99:2268–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet. 2001;27:313–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott–Aldrich Syndrome Protein result in congenital neutropenia. Blood. 2006;108:2182–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Moulding DA, Blundell MP, Spiller DG, et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med. 2007;204:2213–24.PubMedCrossRefGoogle Scholar
  33. 33.
    Beel K, Cotter MM, Blatny J, et al. A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich Syndrome gene. Br J Haematol. 2008, Nov 1 [Epub ahead of print].Google Scholar
  34. 34.
    Ochs HD, Rosen FS. Wiskott–Aldrich Syndrome. In: Ochs HD, Smith CIE, Puck JM, editors. Primary immunodeficiency diseases, a molecular and genetic approach. New York: Oxford University Press; 2007. p. 454–69.Google Scholar
  35. 35.
    Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104:4010–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Washington School of MedicineSeattleUSA
  2. 2.Seattle Children’s Research InstituteSeattleUSA

Personalised recommendations